# The Long-term Study to Evaluate the Safety of Eplerenone in the Treatment of Hypertension in Children Aged 6 to 16 Years

> **NCT00147615** · PHASE3 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 140 (—)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Eplerenone

## Key facts

- **NCT ID:** NCT00147615
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** —
- **Final completion:** 2006-06
- **Target enrollment:** 140 (—)
- **Last updated:** 2020-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00147615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00147615, "The Long-term Study to Evaluate the Safety of Eplerenone in the Treatment of Hypertension in Children Aged 6 to 16 Years". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00147615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*